-
「同位素标记抑制剂」CAS:1246818-18-7|Tolvaptan-d7
作者:德尔塔生物 日期:2025-06-12
生物活性:Tolvaptan-d7 is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].IC50 & Target:V2 Receptor 体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量:455.98Formula:C26H18D7ClN2O3CAS 号:1246818-18-7非标记 CAS:150683-30-0中文名称:托伐普坦 d7运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (536 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Friedman B, Cirulli J.Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan.J Crit Care. 2012 Aug 8. [Content Brief][3]. Inomata T.Tolvaptan (vasopressin receptor antagonist).Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11. [Content Brief][4]. Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa H
-
「同位素标记抑制剂」CAS:1346598-10-4|Etifoxine-d5
作者:德尔塔生物 日期:2025-06-12
生物活性:Etifoxine-d5 is the deuterium labeled Etifoxine. Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents[1][2][3].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Etifoxine-d5 相关抗体:GABARAP AntibodyIP3 Receptor Antibody (YA1596)GABA B Receptor 2 Antibody (YA1733)GABA B Receptor 1 Antibody (YA2418)GAD65 Antibody (YA758)GABA A Receptor alpha 1 Antibody (YA1315)GABA A Receptor beta 2 Antibody (YA1758)GABA Transporter 1 Antibody (YA1795)GAD67 Antibody (YA1807)ABAT Antibody (YA1964)GABA A Receptor alpha 5 Antibody (YA2249)GABA A Receptor beta 1 Antibody (YA2261)BGAT Antibody (YA2741)GABARAPL2 Antibody (YA2882)分子量:305.81Formula:C17H12D5ClN2OCAS 号:1346598-10-4非标记 CAS:21715-46-8中文名称:艾替伏辛-d5运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (534 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacothe
-
「同位素标记抑制剂」CAS:1246818-96-1|(rac)-Dobutamine-d6 hydrochloride
作者:德尔塔生物 日期:2025-06-12
生物活性:(rac)-Dobutamine-d6 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(rac)-Dobutamine-d6 hydrochloride 相关抗体:ADRB2 AntibodySalbutamol Antibody (YA901)Clenbuterol Antibody (YA904)alpha 1a Adrenergic Receptor Antibody (YA2059)分子量:343.88Formula:C18H18D6ClNO3CAS 号:1246818-96-1非标记 CAS:49745-95-1中文名称:多巴酚丁胺盐酸盐 d6 (盐酸盐)运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (530 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.
-
「同位素标记抑制剂」CAS:1246815-74-6|(rac)-Dobutamine-d4 hydrochloride
作者:德尔塔生物 日期:2025-06-12
生物活性:(rac)-Dobutamine-d4 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.(rac)-Dobutamine-d4 hydrochloride 相关抗体:ADRB2 AntibodySalbutamol Antibody (YA901)Clenbuterol Antibody (YA904)alpha 1a Adrenergic Receptor Antibody (YA2059)分子量:341.87Formula:C18H20D4ClNO3CAS 号:1246815-74-6非标记 CAS:49745-95-1中文名称:多巴酚丁胺盐酸盐 d4 (盐酸盐)运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility.
-
「同位素标记抑制剂」CAS:1217629-70-3|Nelfinavir-d3
作者:德尔塔生物 日期:2025-06-12
生物活性:Nelfinavir-d3 (AG1341-d3) is the deuterium labeled Nelfinavir. Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent[1][2][3].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Nelfinavir-d3 相关抗体:CD4 AntibodyTARBP2 Antibody (YA1433)SAMHD1 Antibody (YA1542)SV40 T Antigen Antibody (YA3256)CLEC12A Antibody (YA1419)Tat SF1 Antibody (YA2886)分子量:570.80Formula:C32H42D3N3O4SCAS 号:1217629-70-3非标记 CAS:159989-64-7中文名称:奈非那韦-d3; 那非那韦-d3运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (534 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13(1):76-90. [Content Brief][3]. Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor,
-
「同位素标记抑制剂」CAS:1292841-50-9|Carisbamate-d4
作者:德尔塔生物 日期:2025-06-12
生物活性:Carisbamate-d4 is the deuterium labeled Carisbamate[1].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量:219.66Formula:C9H6D4ClNO3CAS 号:1292841-50-9非标记 CAS:194085-75-1运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (518 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
-
「同位素标记抑制剂」CAS:1217617-73-6|Volinanserin-d4 hydrochloride
作者:德尔塔生物 日期:2025-06-12
生物活性:Volinanserin-d4 (hydrochloride) is the deuterium labeled Volinanserin hydrochlorid. Volinanserin is a potent and selective antagonist of 5-HT2 receptor, with a Ki of 0.36 nM, and shows 300-fold selectivity for 5-HT2 receptor over 5-HT1c, alpha-1 and DA D2 receptors. Volinanserin has antipsychotic activity[1][2].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Volinanserin-d4 hydrochloride 相关抗体:MTNR1A Antibody分子量:413.95Formula:C22H25D4ClFNO3CAS 号:1217617-73-6非标记 CAS:139290-65-6中文名称:氟利色林 d4 (盐酸盐)运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (528 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Sorensen SM, et al. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther. 1993 Aug;266(2):684-91. [Content Brief][3]. Ardayfio PA, et al. The 5-hydroxytryptamine2A receptor ant
-
「同位素标记抑制剂」CAS:1962124-51-1|Tasimelteon-d5
作者:德尔塔生物 日期:2025-06-12
生物活性:Tasimelteon-d5 is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].IC50 & Target:MT2体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量:250.35Formula:C15H14D5NO2CAS 号:1962124-51-1非标记 CAS:609799-22-6中文名称:他司美琼 d5运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Christian Lavedan, et al. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015 Apr;91:142-7. [Content Brief][3]. Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22. [Content Brief]
-
「同位素标记抑制剂」CAS:1325700-11-5|Firocoxib-d4
作者:德尔塔生物 日期:2025-06-12
生物活性:Firocoxib-d4 (ML 1785713-d4) is the deuterium labeled Firocoxib. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects[1].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Firocoxib-d4 相关抗体:COX2 AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCOX IV Antibody (YA867)Cyclooxygenase 1 Antibody (YA2537)Cyclooxygenase 2 Antibody (YA2541)分子量:340.43Formula:C17H16D4O5SCAS 号:1325700-11-5非标记 CAS:189954-96-9中文名称:非罗考昔 d4运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (535 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Steagall PV, et al. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007 Jun;30(3):218-23. [Content Brief][3]. Stock ML, et al. Pharmacokinetics of firocoxib in preweaned calve
-
「同位素标记抑制剂」CAS:1224729-35-4|Lopinavir-d8
作者:德尔塔生物 日期:2025-06-12
生物活性:Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Lopinavir-d8 相关抗体:CD4 AntibodyTARBP2 Antibody (YA1433)SAMHD1 Antibody (YA1542)SV40 T Antigen Antibody (YA3256)CLEC12A Antibody (YA1419)Tat SF1 Antibody (YA2886)分子量:636.85Formula:C37H40D8N4O5CAS 号:1224729-35-4非标记 CAS:192725-17-0中文名称:洛匹那韦-d8运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (534 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief][2]. Cvetkovic RS, et al. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802. [Conte
-
「同位素标记抑制剂」CAS:1132819-16-9|Oxaliplatin-d10
作者:德尔塔生物 日期:2025-06-12
生物活性:Oxaliplatin-d10 is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Oxaliplatin-d10 相关抗体:ERK1/2 AntibodyE-Cadherin Antibody (YA470)Fatty Acid Synthase Antibody (YA766)DYKDDDDK Tag (FLAG) AntibodyGAPDH AntibodyGFP Antibodyp53 Antibody (YA250)RUNX2 AntibodyFerritin Heavy Chain AntibodyCOX2 AntibodyCtip2 AntibodyCyclin D1 Antibody (YA485)Cytochrome C AntibodyRb AntibodyPhospho-Rb (Ser807) Antibodyc-Myc AntibodyCyclin E1 AntibodyRPA32 Antibody (YA679)AIF Antibody (YA636)ALIX AntibodyCDT1 AntibodyCNPase AntibodyCortactin AntibodyCOX IV AntibodyCOX2/Cyclooxygenase 2 AntibodyCyclin A2 AntibodyCyclin B1 Antibody (YA486)DNA-PKcs/PRKDC AntibodyDR5 AntibodyDrosha Antibody分子量:407.35Formula:C8H4D10N2O4PtCAS 号:1132819-16-9非标记 CAS:61825-94-3中文名称:奥沙利铂-d10运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (548 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother
-
「同位素标记抑制剂」CAS:666236-28-8|Ochratoxin A-d5
作者:德尔塔生物 日期:2025-06-12
生物活性:Ochratoxin A-d5 (Phe-OTA-d5) is a deuterium labeled Ochratoxin A (HY-N6788)[1]. Ochratoxin A is one of the mycotoxins typically produced by the species of Aspergillus genus. It is a commonly found secondary metabolite in cereals, coffee, grape must, wine, beer, etc[2].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Ochratoxin A-d5 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量:408.84Formula:C20H13D5ClNO6CAS 号:666236-28-8非标记 CAS:303-47-9中文名称:赭曲霉毒素 A-d5运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (535 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetic
-
「同位素标记抑制剂」CAS:1246816-75-0|Moxifloxacin-d3-1 hydrochloride
作者:德尔塔生物 日期:2025-06-12
生物活性:Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2][3].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Moxifloxacin-d3-1 hydrochloride 相关抗体:MRP2 AntibodyElongation factor 2 Antibody (YA962)Elongation factor 2 Antibody (YA964)PU.1/SPI1 Antibody (YA1116)Sulfadimidine Antibody (YA906)Elongation factor 2 Antibody (YA963)Anthrax Protective gen Antibody (YA1060)Elongation factor 1 gamma Antibody (YA2004)Pulmonary Surfactant Associated Protein D Antibody (YA2107)Cathelicidin Antibody (YA2380)Elongation Factor Ts Antibody (YA2524)Elongation Factor 1A2 Antibody (YA2879)BPI Antibody (YA3068)MetRS Antibody (YA3196)分子量:440.91Formula:C21H22D3ClFN3O4CAS 号:1246816-75-0非标记 CAS:151096-09-2中文名称:盐酸莫西沙星-d3-1;莫西沙星盐酸盐-d3-1运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (539 KB)产品使用指南 (1538 KB)参考文献[1]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88. [Content Brie
-
「同位素标记抑制剂」CAS:1398065-74-1|Monooctyl phthalate-d4
作者:德尔塔生物 日期:2025-06-12
生物活性:Monooctyl phthalate-d4 (Mono-n-octyl phthalate-d4) is a deuterium labeled Monooctyl phthalate (HY-133671). Monooctyl phthalate (Mono-n-octyl phthalate) exhibits antimycobacterial activity with a MIC of 20 μg/mL[1][2].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Monooctyl phthalate-d4 相关抗体:MRP2 AntibodyElongation factor 2 Antibody (YA962)Elongation factor 2 Antibody (YA964)PU.1/SPI1 Antibody (YA1116)Sulfadimidine Antibody (YA906)Elongation factor 2 Antibody (YA963)Anthrax Protective gen Antibody (YA1060)Elongation factor 1 gamma Antibody (YA2004)Pulmonary Surfactant Associated Protein D Antibody (YA2107)Cathelicidin Antibody (YA2380)Elongation Factor Ts Antibody (YA2524)Elongation Factor 1A2 Antibody (YA2879)BPI Antibody (YA3068)MetRS Antibody (YA3196)分子量:282.37Formula:C16H18D4O4CAS 号:1398065-74-1非标记 CAS:5393-19-1中文名称:邻苯二甲酸单辛酯-d4运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief][2]. Muniyan Rajiniraja, et al.In vitro inhibition potential of mono-n-octyl phthalate on Mycobacterium tuber
-
「同位素标记抑制剂」CAS:866864-06-4|Mono(5-carboxy-2-ethylpentyl) phthalate-d4
作者:德尔塔生物 日期:2025-06-12
生物活性:Mono(5-carboxy-2-ethylpentyl) phthalate-d4 (MECPP-d4) is a deuterium labeled Mono(5-carboxy-2-ethylpentyl) phthalate (HY-133675). Mono(5-carboxy-2-ethylpentyl) phthalate (MECPP) is a metabolite of Di-(2-ethylhexyl) phthalate (DEHP). Di(2-ethylhexyl) phthalate is the predominant plasticizer added to rigid polyvinyl chloride (PVC) to impart flexibility, temperature tolerance, optical clarity, strength and resistance to kinking[1][2][3].体外研究(In Vitro):氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Mono(5-carboxy-2-ethylpentyl) phthalate-d4 相关抗体:FMO3 Antibody (YA1992)分子量:312.35Formula:C16H16D4O6CAS 号:866864-06-4非标记 CAS:40809-41-4运输条件:Room temperature in continental US; may vary elsewhere.储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (535 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief][2]. Sjöberg P, et al. Effects of di-(2-ethylhexyl) phthalate and five of its metabolites on rat testis in vivo and in in vitro. Acta Pharmacol Toxicol (Copenh). 1986;58(3):225-233. [Content Brief][3]. Van Vliet ED, et al. A review of alternatives to di (2-ethylhexyl) phthalate-containing medical devices in the neonatal intensive care unit [pub